UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050083
Receipt number R000057054
Scientific Title Effects of Far Infrared Radiation Air Conditioning on Sleep Dissatisfiers
Date of disclosure of the study information 2023/01/19
Last modified on 2024/01/19 11:18:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of Far Infrared Radiation Air Conditioning on Sleep

Acronym

Sleep test

Scientific Title

Effects of Far Infrared Radiation Air Conditioning on Sleep Dissatisfiers

Scientific Title:Acronym

Sleep test

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Empirical Study on Sleep Improvement by Far Infrared Radiation Air Conditioning

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sleep-related indicators

Key secondary outcomes

Sleep Related Questionnaire


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Other

Interventions/Control_1

Sleep for 4 days in an environment with a far-infrared radiation air conditioning system

Interventions/Control_2

Sleep for 4 days in an environment with air conditioning system

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Normal men and women
Subjects who are aware of their sleep problems.
Subjects who have been fully informed of the purpose and content of the study, have the capacity to consent, and have voluntarily volunteered to participate based on a thorough understanding of the purpose and content of the study, and have given their consent to participate in the study in writing.

Key exclusion criteria

-Subjects who are currently receiving treatment (including medication) for any disease.
-Subjects who have been diagnosed with sleep disorders such as insomnia or sleep apnea syndrome and are taking drugs such as sleep inducers or insomnia medications (including OTC drugs as well as prescription drugs) or are receiving treatment with CPAP or mouthpieces, etc.
-Those who regularly use foods for specified health use, functional foods, supplements, or health foods (GABA-containing foods, lactic acid bacteria drinks, theanine-containing foods, crocetin-containing foods, polyphenol-containing foods, etc. that claim to improve sleep) that may affect the research at least 3 times a week. Subjects who regularly consume GABA-containing foods, lactic acid bacteria beverages, theanine-containing foods, crocetin-containing foods, polyphenol-containing foods, etc.) three or more times a week, and who are unable to limit their intake during the study period
-Subjects suspected of having a chronic or acute serious infectious disease
-Subjects who are scheduled to be vaccinated during the study period
-Subjects who work late at night or in shift work
-Subjects who habitually drink alcohol more than 3 times a week and more than 1 sake equivalent (beer: 1 medium bottle, whiskey: 1 double, shochu: 0.6 sake)
-Subjects with extremely irregular eating habits
-Subjects with a BMI of 30 or higher
-Subjects who are currently participating in a clinical study of other drugs or health foods, and who are scheduled to participate in another clinical study within one month after the completion of the study or after consent to participate in the study.
-Subjects who are unable to stay at the designated research site for a certain period of time
-Subjects who are otherwise deemed by the Principal Investigator to be inappropriate for participation in this study.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name seiji
Middle name
Last name miyamura

Organization

MIYA JAPAN.CO.,LTD

Division name

Chairman and Representative Director

Zip code

938-0801

Address

3545 Ogio, Kurobe City, Toyama, 938-0801,Tokyo

TEL

0765-32-3233

Email

m-miyamura@miya-japan.co.jp


Public contact

Name of contact person

1st name riku
Middle name
Last name miyamura

Organization

MIYA JAPAN.CO.,LTD

Division name

Marketing Department

Zip code

938-0801

Address

3545 Ogio, Kurobe City, Toyama, 938-0801,Tokyo

TEL

0765-32-3233

Homepage URL


Email

r-miyamura@miya-japan.co.jp


Sponsor or person

Institute

MIYA JAPAN.CO.,LTD

Institute

Department

Personal name



Funding Source

Organization

MIYA JAPAN.CO.,LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Chiyoda Paramedical Care Clinic

Address

2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan

Tel

03-5297-5548

Email

IRB@cpcc.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 11 Month 29 Day

Date of IRB

2022 Year 11 Month 18 Day

Anticipated trial start date

2023 Year 01 Month 19 Day

Last follow-up date

2023 Year 09 Month 30 Day

Date of closure to data entry

2023 Year 09 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 01 Month 19 Day

Last modified on

2024 Year 01 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000057054


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name